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Summary Reactive oxygen metabolites are implicated in the initiation and promotion of cancer. In addition, oxidant scavengers, such as
manganese - (Mn-SOD) and copper/zinc - superoxide dismutase (Cu/Zn-SOD), are thought to contribute to colorectal cancer treatment
response. In the present study, the prognostic significance of the Mn- and Cu/Zn-SOD antigen content of normal mucosa and carcinomas of
163 patients with colorectal cancer was evaluated in comparison with major clinicopathological parameters, with respect to the 5-year overall
survival. The Mn-SOD content of carcinomas was found to be significantty higher than that of normal mucosa, whereas there was no
difference in the Cu/Zn-SOD content between the normal mucosa and carcinomas. No association was demonstrable between the Mn-SOD
and Cu/Zn-SOD content of the tissues and the assessed clinicopathological parameters (gender, age, localization, differentiation grade,
diameter and Dukes' stage), with the exception of the Cu/Zn-SOD and the differentiation grade of the carcinomas. Univariate analysis showed
that a high Mn-SOD content of carcinomas was associated with a poor 5-year overall survival of the patients with colorectal cancer.
Multivariate analysis including all clinicopathological parameters revealed that this Mn-SOD parameter was prognostically independent. The
Mn- and Cu/Zn-SOD content of normal mucosa and the Cu/Zn-SOD content of carcinomas were not associated with the overall survival of the
patients. In conclusion, this study demonstrates that for patients with colorectal cancer the Mn-SOD content of colorectal carcinomas has a
significant prognostic value that is independent from major clinicopathological parameters, including Dukes' stage.
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Reactixve oxygen metabolites (ROMs). i.e. hydrogen peroxide.
superoxide anion (O,) and hydroxyI radical (OH). are inevitable
(by)products ofaerobic metabolism and are formed continuousIy in
Vixo (Sahu. 1991). A delicate balance betxxteen the Peneration of
these toxic and unstable metabolites and the lexels of endogenous
antioxidants is of critical importance for normal cell functionin.
When produced excessively or dungnc deficient antioxidant
defences. these ROMs can mediate DNA damace. lipid peroxida-
tion. enzyme oxidation. etc.. leading to cellular destruction.
chromosomal aberrations and finally to cancer (Slater. 1984: Borek.
1987: Farber et al. 1990: Sahu. 1991: Guyton and Kensler. 1993:
Wiseman and Hallixxell. 1996). Paradoxically. chemotherapy. radia-
tion therapy. photodynamic therapy and some cytokine therapies.
forexample tumour necrosis factor a (TNF-c). haxe been shown to
exert part of their therapeutic efficacy by generating large amounts
ofthese noxious radicals to kill tumour cells (Oberley and Buettner.
1979: Petkau. 1987: Oberley. 1990: Sangeetha et al. 1990).
Therefore. endogenous antioxidant proteins. as a primary defence
against these ROM-generating anti-cancer therapies. might play an
important role in colorectal cancer therapy resistance.
One of the most important enzymes invol%-ed in the primary
cellular defence aoainst these ROMs is superoxide dismutase
(SOD). which detoxifies superoxide anion to hydrogen peroxide.
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Studies with cell lines and animal models rexealed the relexance
of antioxidants. for example SOD. w-ith respect to the effectixve-
ness and side-effects of colorectal cancer therapies (Petkau. 1987:
Hauser et al. 1990: Eastgate et al. 1993: Hirose et al. 1993: Kizaki
et al. 1993: Urano et al. 1995: Wong. 1995). In humans. SOD is
known to be present in at least two forms. a constitutiVe cvto-
plasmic copper/zinc (Cu/Zn)-SOD and an inducible mitochondrial
manganese (Mn -SOD (McCord and Fridoxich. 1969: Fridoxich.
1975: Beyer et al. 1991: Farber. 1994). We recently showed that
colorectal adenomas. carcinomas and liver metastases are charac-
terized by a significantly increased antigen and activity level of
Mn-SOD compared with normal colorectal mucosa. In contrast. no
major differences wxere found in the Cu/Zn-SOD levels (Janssen et
al. 1997). Advances in the early diagnosis. screening procedures of
hiah-risk individuals. the surgical approach and adjuxant therapy.
have hardly changed the prognosis of colorectal cancer in the last
few decades (Sinmgce and Mulder. 1991: Greenwald. 1992: Van
Triest et al. 1995: Winawer. 1995). Until recently. only Dukes' and
related stage classifications have been accepted as the most impor-
tant proanostic parameters for the survival of these patients (Jass
et al. 1986: Beahrs. 1992: Deans et al. 1992: Ponz de Leon et al.
1992: Bosman. 1995). Howexver. additional functionally relexant
prognostic factors that predict clinical outcome and support
treatment planning for subgroups of patients with colorectal
cancer miaht be Xerv useful.
In the present study. we determined the Cu/Zn-SOD and Mn-
SOD antigen content of normal mucosa and carcinomas of 163
patients with colorectal cancer. and evaluated their relation with
clinicopathological parameters and their prognostic xalue for the
5-year oxerall surnix al ofthe patients.
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MATERIALS AND METHODS
Patients and study design
All 163 patients (69 women and 96 men) were operated on for a
histologically proven adenocarcinoma of the colorectum at the
Departmnt ofOncologic Surgery ofthe Leiden University Medical
Center. Immediately after resection, fresh samples from the mid-
central non-necrotic part of the carcinoma and/or from normal
mucosa. taken approximately 10 cm from the tumour, were frozen
and stored at -70°C until extraction. when available for research
purposes. From this group ofpatients, several clinical and patholog-
ical data were evaluated and registered or retrieved from their data
files. The tunours were histologically classified according to
Dukes' stage, as modified by Astler and Coller (1954). There were
seven patients with Dukes' stage A. 21 with B,, 61 with B,. 17 with
C,. 37 with C,. and 20 patients with Dukes' stage D cancer, corre-
sponding to UICC (Hennanek and Sobin, 1992) TNM stages 0
(Dukes' A), I (Dukes' B,), II (Dukes' B,) mI (Dukes' C, and C,)
and IV (Dukes' D). Thirty-seven patients with Dukes' stage B or C
tumours received additional radio- (n = 27) orchemoteay (n = 4)
or both (n = 2), after the primary resection or during follow-up, or
had to have a second resection (n = 9), based on clinicopathological
indications. All patients entered the study at operation date and
follow-up was at least 5 years. or shorer in the event ofdeath.
Ninety-five patients (58.3%. 38 women and 57 men) died
during follow-up and 68 (41.7%, 31 women and 37 men) were still
alive at the common closing date of the follow-up. The overall
survival ofthe patients gradually decreased from those with carci-
nomas classified as Dukes' A (85.7%), Dukes' B, (71.4%), Dukes'
B, (49.2%). Dukes' C, (41.2%). Dukes' C, (27.0%) to those with
Dukes' D carcinomas (0.0%). indicating a representative popula-
tion ofcolorectal cancer patients.
Tissue extraction and protein con traion
Extractions were prepared from 50-100 mg wet tissue samples.
The samples were wet weighed, and 1 ml of 0.1 M Tris-HCI,
pH 7.5, with 0.1% (v/v) Tween 80 per60 mg ofsample was added.
The tissue was homogenized for 2 min on ice in a Potter S (B
Braun). The homogenates were centrifuged twice at 8000g for
2.5 min at 4°C and the final supernatants were stored at -70°C.
The protein concentration of the supematants was determined
using the method of Lowry et al (1951). The intra-tumour coeffi-
cient ofvariation ofthe procedure was assessed by processing six
adjacent tissue parts from six different tumours and was found to
be 10% (range 4-15%) for the protein extraction.
Standards and antibodies
The standards used were human recombinant (hr) Mn- and Cu/Zn-
SOD, kindly provided by Dr Z Yavin from the Kyriat Weizmann
Institute, Rehovot. Israel. The monospecific antibodies raised in
rabbits showed no cross reactivity between the two SOD forms
(Mn vs Cu/Zn) andprovided no signal with otherproteins oftissue
homogenates on Western blotting.
Enzyme-linked immunosorbent assay (EUSA) for
Cu/Zn-SOD
The Cu/Zn-SOD antigen level was determined by a modified
ELISA. as described previously (Mulder et al. 1990; G6tz et al,
1996). Microtitre plates (Dynatech Laboratories. USA: M129A)
were coated with affmopurified goat a-human Cu/Zn-SOD
(10 jig ml-F in 0.05 M carbonate buffer, pH 9.6) overnight at 4°C.
followed by PBST/gelatine [phosphate-buffered saline (PBS)
containing 0.05% (v/v) Tween 20 and 0.2% (v/v) gelatine] for
30 min. After washing, 100gl of each homogenate diluted 1:400
in PBST/gelatin was added in duplicate followed by incubation for
2 h. The plates were then washed and rabbit a4hr)Cu/Zn-SOD
polyclonal antiserum (1:2500 dilution in PBST) was added to the
wells and incubated for 1 h. The final antibody, a polyclonal goat
a-rabbit IgG conjugated to horseradish peroxidase (Dakopatts.
P448, 1:5000 dilution in PBST) was preincubated before use with
0.2% preimmune goat serum for 30 min. After an incubation
period of 1 h with the final antibody, the plates were coloured with
a solution of 40 mg orthophenylenediamine and 40gl hydrogen
peroxide in 100 ml citric acid/phosphate buffer, pH 5.0, for
30 min. The reaction was terminated using 50gl 2.5 M sulphuric
acid. The optical density was read at 492 nm on a Titertek
Multiscan (Flow Laboratories. UK) plate reader. The Cu/Zn-SOD
concentration was calculated from a standard curve between 1.25
and 30 ng ml-' (hr)Cu/Zn-SOD and expressed per mg protein of
the homogenate. The intra- and inter-assay coefficients of varia-
tion ofthis ELISA were 4% and6% respectively. The intra-tumour
coefficient of variation of the Cu/Zn-SOD level was found to be
17% (range 5-32%).
EUSA for Mn-SOD
This procedure is similar to the Cu/Zn-SOD ELISA described
previously (Gotz et al, 1996). The plates were incubated overnight
at 40C with an affinopurified rabbit a-(hr)Mn-SOD polyclonal
antibody (10jg mlF in 0.05 m carbonate buffer, pH 9.6). The
homogenates were diluted 1:150 and incubated in duplicate for 2 h
at room temperature with PBST as assay diluent The standard line
of (hr)Mn-SOD ranged from 1.25 to 40 ng ml-'. After incubation
with the tissue homogenates, the plates were washed and incu-
bated for90 min with a rabbita4hr)Mn-SOD coupled with horse-
radish peroxidase (1:250 dilution in PBST). After a final wash.
bound antibodies were detected as described for Cu/Zn-SOD. The
intra- and inter-assay coefficients ofvariation ofthis ELISA were
5% and 10% respectively. The intra-tumour coefficient of
variation ofthe Mn-SOD level was 21% (range 9-35%).
Statistical analyses
The significance ofthe differences in the mean superoxide dismu-
tase antigen levels between different patient and sample groups
was assessed by ANOVA and the unpaired Student's t-test, with
separate variance estimates ifthe standard deviations were signifi-
cantly different according to the F-test. For the statistical survival
analyses ofthis group ofpatients, the clinicopathological parame-
ters were dichotomized as follows: Dukes' stage was divided into
Dukes A/B vs CID; tumour localization in the colon into right-
sided (from caecum to splenic flexure) and left-sided (from splenic
flexure to the end of the rectum): diameter of the tumour into
< 4 cm vs > 4 cm: tumour differentiation into wellmoderately vs
poorly differentiated; and gender into men vs women. The cut-off
points of the age and the significant SOD parameters were deter-
mined by slowly increasing the level until the point of best
discrimination was found. i.e. the optimal dichotomization.
Univariate survival analysis wasperformed with the Coxpropor-
tional hazard model (Cox. 1972). using the SPSS 6.0 statistical
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Figure 1 Frequency distributon of the normal colorectal mucosa (n = 150.
open bars) and the colorectal caranomas (n = 156, black filled bars)
according to their Mn-SOD antgen level
softxvare package (SPSS. Chicago. IL. USA). resultinc in identifi-
cation of covariates which significantly correlated with the overall
survival ofthe patients.
Multivariate survival analvses were performed usinc the Cox
proportional hazards method by separately addinc the significant
SOD variables to the six dichotomized clinicopathological
parameters (i.e. age and gender of the patients. and Dukes' stage.
diameter. differentiation and localization of the tumours). Overall
survival curves were constructed using, the method of Kaplan and
Meier (1958). The statistical significance of the difference in
survival ofthe groups was calculated using the log-rank test.
Differences were considered significant w-hen the P-value was
.0.05.
RESULTS
Mn-SOD and Cu/Zn-SOD concentrations
The Mn-SOD content of the carcinomas (714 + 34 ne m-1
protein. n = 156) was found to be significantly (P < 0.0005) higher
than that of the normal mucosa (257 + " no mg-' protein. n =
150). Despite an overlap in the absolute Mn-SOD level between
carcinomas and normal mucosa (Figure 1). a largue majority
(82.5%) ofthe tumours had a higher level than their correspondinc
normal mucosa. Concerning the Cu/Zn-SOD content. there was no
significant difference between the mean level of the carcinomas
(527 ± 19 ng mg-1 potein. n = 155) and that ofthe normal mucosa
(535 ± 17 ng, mg-1 protein. n = 149).
When the nornal mucosa and carcinomas w-ere divided into two
subgroups according, to the survival or the dichotomized clinico-
pathological parameters. no significant differences in Mn-SOD
concentration were noticed. There were also no significant differ-
ences in the Cu/Zn-SOD level except for the concentration of the
poorly differentiated carcinomas. w-hich was significantly lower
than that ofthe well/moderatel differentiated carcinomas (Table 1).
SOD concentrations and survival
Optimal dichotomization ofthe Mn-SOD concentration ofthe carci-
nomas resultedin twocut-offpoints. at 330 and 975 ng mg-1 protein.
At both cut-offpoints. a high Mn-SOD level ofthe carcinomas uas
associated with a relatively poor survival of the patients in the
Table 1 Mn-SOD and Cu/Zn-SOD antigen level (ng mg-' protein) in normal mucosa and colorectal carcinomas dichotomized according to various
clinicopathological parameters. Resufts shown are mean values ± s.e.
Normal mucosa Carcinoma
Parameter dichotomized Mn-SOD (n) Cu/Zn-SOD (n) Mn-SOD (n) Cu/Zn-SOD (n)
Patients
Alive 288 |42 (62) 554 ± 26 (62) 664 ± 52 (67) 537 ± 29 (67)
Deceased 236 24 (88) 521 ± 23 (87) 752 ± 45 (89) 519 ± 27 (88)
Gender
Women 283 _ 36 (65) 532 ± 22 (65) 728 49 (67) 529 ± 28 (66)
Men 237±28 (85) 538_25 (84) 704+47 (89) 525_27 (89)
Age (years)
< 66.1 247 - 37 (60) 524 + 29 (60) 684 - 47 (66) 513 26 (65)
>66.1 265±28 (90) 543+21 (89) 736_48(90) 537_28 (90)
Localization
Right colon 244 ± 30 (55) 559 29 (55) 747 59 (57) 516 36 (57)
Left colon 265 ± 31 (95) 521 21 (94) 695 41 (99) 532 23 (98)
Differentiation
Well/moderate 275 ± 30 (76) 539 ± 24 (75) 653 -44 (80) 571 -30 (80)
Poor 240 33 (74) 532 ±25 (74) 779±51 (76) 479±24 (75)a
Diameter
<4cm 263 55 (32) 511 ±37 (32) 744 +67 (35) 494 35 (34)
> 4cm 256 24 (118) 542 19 (117) 706 ± 39 (121) 536 23 (121)
Dukes' stage
AB 273 32 (82) 545 22 (81) 674 ± 43 (84) 548 ± 29 (81)
CD 239 31 (68) 524 27 (68) 761 ± 53 (72) 501 ± 25 (71)
aCompared withwelL/moderate (P= 0.02).
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Table 2 Univanate and multivanate analysis of the categorized Mn-SOD concentration of the carcinomas in relation to overall survival of patients with
colorectal cancer
Mn-SOD Survivors/total Median survival Cox hazard ratio (95% Cl, P-value)
anKigena rfn(%) (months)
univariate multivariate
< 330 21/34 (61.8) 64.5
> 330 46/122 (37.7) 35.5 2.0 (1.1-3.7. 0.02) 1.9 (1.1-3.5. 0.03)
< 975 55/116 (47.4) 59.0
> 975 12/40 (30.0) 30.5 1.5 (1.0-2.4,0.07) 1.2 (0.7-1.8. NS)
< 330 21/34 (61.8) 64.5
330-975 34/82 (41.5) 45.0 1.9 (1.0-3.5, 0.05) 1.9 (1.0-3.6. 0.04)
> 975 12/40 (30.0) 30.5 2.4 (1.2-4.6, 0.01) 1.9 (1.0-3.7. 0.07)
ang mg-' protein; Cl. confidence interval; NS, notsignificant. Multvanate analysis was performed by adjusting the Mn-SOD parameter to the cIinicopatho#xgical
parameters (gender, age. localizabon, differentiation grade. diameter, and Dukes' stage).
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Figure 2 Overall survival curves according to high (>975 ng mg-' protein),
intermediate (330-975 ng mg- protein) and low (<330 ng mg- protein) Mn-
SOD level in carcinomas of patients with colorectal cancer. Values are the
number of patients alive/deceased at the end of the follow-up. Statistical
signifiance according to te log-rank test
univariate anals-sis (Table 2). Based on these txwo cut-offpoints. the
Mn-SOD concentration was stratified into three subgroups with
sufficient numbers in each group: the first group included carci-
nomas with a Mn-SOD level < 330 ng m -' protein. the second
group contained between 330 and 975 ng mg-1 protein. and the third
group had > 975 ng mg-' protein. Unixariate Cox analysis. evalu-
ating the prognostic xalue of Mn-SOD as a stratified variable.
showed that patients with carcinomas containincr < 330 ng Mn-SOD
per mg protein had a significantly longer survival time than those
with a level of > 975. Those patients with carcinomas containing a
Mn-SOD antigen level betxeen 330 and 975 nc mg-1 protein
showed an intermediate survival (Figure 2 and Table 2).
The multivariate Cox analyses of the dichotomized clinicopatho-
logical parameters revealed that only Dukes stage of the tumour
[hazard ratio 2.8 (95% confidence intersal 1.8-4.3). P<0.00005]
and age of the patient [hazard ratio 2.1 (95%c confidence intersal
1.4-3.4). P = 0.001] were independently associated with survival.
The dichotomized and stratified Mn-SOD vanables were finally
also adjusted to all the assessed clinicopathological parameters.
In this multivanrate analysis. a high Mn-SOD concentration (i.e.
> 330 ngy mg-I protein) remained associated (0.03 < P < 0.07) with a
relatively poor 5-year survival ofthe patients. indicating its indepen-
dent prognostic value (Table 2). Concerfning the Mn-SOD antigen
level in normal mucosa and the Cu/Zn-SOD antiaen concentration of
the carcinomas and normal mucosa. no cut-off point. discnimating,
between survivors and non-surxvixVors. could be identified.
Table 3 shows the multivariate analyses of the Mn-SOD para-
meter within subgroups of patients according, to their Dukes' stage.
With regard to the patients with Dukes stage B or C carcinomas. all
tested levels had aprognostic salue with the exception ofthe higher
cut-off point (> 975 vs < 975 ng mo-1 protein). Furthermore. this
table indicates that within the subgroupofpatients with Dukes' stage
B the highercut-offpoint (> 975 xrs < 975 ng mg-- protein and > 975
vs < 330 ng mo-1 protein) had a prognostic impact. whereas within
the subgroup ofpatients with Dukes stage C the lower cut-offpoint
(330-975 vs < 330 ng mg-1 protein and to a lesser extent > 330 vs
< 330 ng mg-1 protein) was ofprognostic value. Within the subgroup
of patients with Dukes' stage B or C. the survival of those who
received additional treatment after the primarv surgical resection
v as significantly (P=0.01 ) poorerthan the survival ofthose patients
Table 3 Multivariate analysis based on the Mn-SOD concientration of the carcinomas within Dukes' stage subgroups of patients with colorectal cancer in
relation to the overall survival
Mn-SOD (ng mg- protein)
> 330 vs < 330 > 975 vs < 975 330-975 vs < 330 >975 vs < 330
Dukes
C vs B 2.0 (1.0-3.8, 0.04)a 1.3 (0.8-2.2. NS) 1.9 (1.0-3.8, 0.07) 2.1 (1.0-4.5. 0.05)
B2 vs B. 1.5 (0.6-3.5, NS) 2.4 (1.1-5.4, 0.03) 1.1 (0.4-2.8, NS) 2.6 (1.0-6.9. 0.06)
C2vs C 2.5 (0.8-7.7. 0.1) 1.0 (0.4-2.2, NS) 2.7 (0.8-8.8, 0.009) 2.1 (0.6-7.5. NS)
aCox hazard ratio (95°hconfidence interval, P-value): NS. not significant. Mutfivariate analysis was performed by adjusting the Mn-SOD parameter to the
clinicopathoogical parameters (gender, age, localization, differentiation grade, diaameter and Dukes' stage).
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who did not receive an additional therapy (27.0% vs 52.5%).
However. there was no difference in the Mn-SOD content of the
carcinomas between these two groups ofpatients [751 ± 70 (n = 36)
vs 699 ±44 ng mg-' protein (n = 96) respectively]. From the 32)
patients who had had additional radio- and/or chemotherapy. nine
were still alive and 23 had died at the end offollow-up. Between the
carcinomas of these patients. there was a remarkable. though not
statistically significant (P = 0.14). difference in the Mn-SOD
content. respectively 591 ± 139 and 841 ±86 ng mg-' protein.
DISCUSSION
Colorectal carcinomas were found to be associated with a significant
increase in the Mn-SOD contentcompared with the nonnal mucosa.
whereas there was no significant difference in the Cu/Zn-SOD
content between the normal mucosa and carcinomas. In addition. the
Mn-SOD level in the tumours was found to be an independent
prognostic indicator for the overall survival ofthe patients.
An increased level of ROMs in colorectal cancer development
and/or stimulation by cytokines. such as TNF or interleukin 1.
produced by the cancerous cells themselves or by infiltrating
macrophages. probably act as autocrine factors to induce Mn-SOD
in the carcinomas (Wong and Goeddel. 1988: Salim. 1992:
Valentine and Nick. 1992: Mohnenti et al. 1993: Qureshi et al. 1994.
Yoshimi et al. 1994: Warner et al. 1996). Although the exact mecha-
nisms that cause the alterations in the antioxidant enzyme levels.
particularly Mn-SOD. in cancer are not yet known (as reviewed by
Oberley and Oberley. 1997). they may be clinically highly relevant
with regard to patient selection and the administration and develop-
ment of(neo-)adjuvant therapy in colorectal cancer.
Except for the Cu/Zn-SOD content of poorly differentiated
carcinomas. which appeared to be lower than that ofwell-differen-
tiated or moderately differentiated carcinomas. no association
between the Mn-SOD and Cu/Zn-SOD content of the carcinomas
and any of the six assessed clinicopathological parameters was
noticed. indicating their independent regulation. Optimal dichito-
mization of the Mn-SOD content of the carcinomas in relation to
survival resulted in two cut-off points. The Mn-SOD parameter
could thus be analysed either as a dichotomized parameter or as a
variable comprising three categories. Univariate analysis of this
Mn-SOD parameter revealed a significant association between a
high Mn-SOD antigen content of the colorectal carcinomas and a
relatively poor 5-year overall survival. In contrasts for the Cu/Zn-
SOD content of the carcinomas. it was not possible to identify a
cut-off point discriminating between survivors and non-survivors.
Multivariate Cox's proportional hazard analysis with the six
dichotomized clinicopathological parameters (gender. age. local-
ization. differentiation grade. diameter and Dukes' stage) revealed
only staging and patient age as independent prognostic variables.
Adding the Mn-SOD content of the carcinomas as a parameter to
this multivariate model revealed. for the first time. the independent
prognostic value of Mn-SOD for the overall 5-year survival of
patients with colorectal cancer.
Recognition of prognostic factors is of great significance for
outcome prediction and treatment planning in colorectal cancer.
which is the second leading cause of cancer-related death in the
Western world. The Dukes' pathological staging system. either in its
original or in its modified fomi. is still the most powerful predictor
offinal outcome in colorectal cancer patients against which all other
prognostic factors in colorectal cancer should be assessed. This
pathological staging system. based upon tumour invasiveness.
lymph nodeinvolvement and distant metastases. is also the basis for
advocating additional therapy after radical surgery. offering adju-
vant chemo-. immuno- and/or radiotherapy only to those patients
with prognostically less favourable disease (Jass et al. 1986: Beahrs.
1992: Deans et al. 1992: Ponz de L6on et al. 1992). However. until
now these therapeutic modalities have been successful only in a
minority of the cases. and the overall survival rate of colorectal
cancer has not improved dramatically in the last decade (Bosman.
1995). Therefore. it is of crucial impotance to identify additional
prognostic parameters that also relate to treatment response.
enabling better patient selection for adjuvant therapy.
Little is known from the literature about the prognostic value
of endogenous antioxidants. including SOD. to the survival of
(colorectal) cancer patients. Ofner et al (1994) evaluated the prog-
nostic significance of immunohistochemical expression of metal-
lothionein (MT). a hydroxyl radical-scavenging metalloprotein. in
colorectal adenocarcinomas. They found a statistically significant
correlation ofhigh MT expression and favourable clinical outcome
in a univariate analysis but not in a multivariate analysis with
Dukes' stage as a stratification factor. There have been several
reports about the clinical significance of the Mn-SOD serum level
as a tumour marker for cancer patients. Ishikawa et al (1990) found
elevated Mn-SOD levels in the serum of patients with epithelial
ovarian cancer and these correlated with the clinical stage of the
disease and with the response to treatment. Similarly. Schadendorf
et al (1995) reported elevated serum Mn-SOD levels in patients
with malignant melanoma compared with normal controls. and
these elevated Mn-SOD concentrations corresponded to tumour
load and correlated with progression of malignant melanoma.
Furthermore. an increased SOD activity level of carcinomas was
found to be associated with the malignant intensity of colorectal
carcinomas (Satomi et al. 1995). In our present study, however. we
could not demonstrate any significant association between the
Mn-SOD content of the carcinomas. primarily localized in
the malignant epithelial cells (unpublished observation). and the
malignancy parameters ofthe tumour (i.e. Dukes' stage, differenti-
ation grade. diameter. etc.). Very recently. Landriscina et al (1996)
reported enhanced expression of Mn-SOD. evaluated by Western
blotting and immunohistology. in neuroepithelial brain tumours
which correlated with the grade of differentiation. Furthermore.
they indicated that a low Mn-SOD level in glioblastomas was
associated with a longer survival and a high level with a shorter
survival of the patients. Interestingly. one of these brain tumours
was found to be a metastasis of colon cancer which expressed
a high level Mn-SOD. Our study extends these observations.
indicating that colorectal tumours are not only characterized by
increased Mn-SOD levels but that this SOD isoform also acts as a
functionally relevant and independent prognostic parameter to the
overall survival of these patients.
Because ROMs may be involved in the mechanism(s) by
which several anti-cancer treatments. including chemotherapy.
immunotherapy. photodynamic therapy and radiotherapy. exert
their therapeutic effect (Oberley and Buettner. 1979: Petkau. 1987:
Oberley. 1990: Sangeetha et al. 1990). it can be hypothesized that
a relatively high Mn-SOD level ofthe colorectal carcinomas in our
study contributes to tumour cell resistance and therapy insensi-
tivity resulting in a poor clinical outcome. In support of this
hypothesis. Nakano et al (1996) recently demonstrated that the
Mn-SOD level of cancer cells was an important prognostic factor
in radiation therapy sensitivity for patients with cervical carci-
noma. i.e. cervical tumours expressing Mn-SOD were associated
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with a significantly poorer survival than those negative for Mn-
SOD. Also. other studies have shown that SOD protects cells in
tissue and laboratory animals against the harmful (side-)effects of
ionizing radiation (Petkau, 1987; Eastgate et al, 1993; Hirose etal,
1993; Wong, 1995), cytokines (Wong et al, 1989; Hauser et al,
1990; Hirose et al, 1993; Kizaki et al. 1993), and several anti-
cancer drugs (Hirose et al, 1993; Zyad et al, 1994). It is supposed
that Mn-SOD removes toxic superoxide radicals and protects
against the damaging effects of these oxygen radical-mediated
treatments. In our study, there was no significant difference in the
Mn-SOD content of the carcinomas between those patients who
received additional treamnt and those who did not after the
primary surgical resection, within the subgroup of patients with
Dukes' stage B or C. The relatively poor survival of the patients
who did receive additional teatment, because ofthe clinicopatho-
logical indication of incomplete resection and/or tumour recur-
rence, was to be expected. The observation that the patients who
were given additional radio- and/or chemotherapy and were still
alive at the end offollow-up had considerable lower tumour Mn-
SOD levels than those who had died, however, conveys the
impression that this SOD isofonn contributes to therapy resistance
in colorectal cancer.
In conclusion, the increased Mn-SOD content of colorectal
carcinomas can be regarded as an independent prognostic para-
meter for overall survival in colorectal cancer. Further larger
studies, for example in which the Mn-SOD content ofcarcinomas
or cell lines will be related to (adjuvant) therapy sensitivity and
efficacy, are necessary to elucidate the underlying mechanism.
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